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Abstract
Background: Diabetes in pregnancy, which includes gestational diabetes mellitus (GDM) and type 2 diabetes
mellitus (T2DM), is associated with poor outcomes for both mother and infant during pregnancy, at birth and
in the longer term. Recent international guidelinesr e c o m m e n dc h a n g e st ot h ec u r r e n tG D Ms c r e e n i n g
criteria. While some controversy remains, there appears to be consensus that women at high risk of T2DM,
including indigenous women, should be offered screening for GDM early in pregnancy, rather than waiting
until 24-28 weeks as is current practice. A range of criteria should be considered before changing screening
practice in a population sub-group, including: prevalence, current practice, acceptability and whether
adequate treatment pathways and follow-up systems are available. There are also specific issues related to
screening in pregnancy and indigenous populations. The evidence that these criteria are met for indigenous
populations is yet to be reported. A range of study designs can be considered to generate relevant evidence
for these issues, including epidemiological, observational, qualitative, and intervention studies, which are not
usually included within a single systematic review. The aim of this paper is to describe the methods we used
to systematically review studies of different designs and present the evidence in a pragmatic format for
policy discussion.
Methods/Design: The inclusion criteria will be broad to ensure inclusion of the critical perspectives of indigenous
women. Abstracts of the search results will be reviewed by two persons; the full texts of all potentially eligible
papers will be reviewed by one person, and 10% will be checked by a second person for validation. Data
extraction will be standardised, using existing tools to identify risks for bias in intervention, measurement,
qualitative studies and reviews; and adapting criteria for appraising risk for bias in descriptive studies. External
validity (generalisability) will also be appraised. The main findings will be synthesised according to the criteria for
population-based screening and summarised in an adapted “GRADE” tool.
Discussion: This will be the first systematic review of all the published literature on diabetes in pregnancy among
indigenous women. The method provides a pragmatic approach for synthesizing relevant evidence from a range
of study designs to inform the current policy discussion.
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Gestational diabetes mellitus (GDM) is defined as “any
degree of glucose intolerance with onset or first recogni-
tion during pregnancy” [1]. GDM can be a temporary
glucose intolerance, as a result of hormonal changes in
pregnancy, or type 2 diabetes mellitus (T2DM) that has
not previously been diagnosed. Diabetes in pregnancy
(DIP) includes both GDM and T2DM, which may or
may not have been previously diagnosed, and type 1 dia-
betes mellitus.
DIP is associated with increased risks at birth for the
mother (caesarean section)[2] and the infant (macroso-
mia, hypoglycaemia) [2]. Women with GDM are at high
risk for T2DM after pregnancy [3,4], and GDM is often
identified as an early step in the “natural history” of the
progression to T2DM. Children born to women with
DIP have higher risks for obesity and for T2DM in later
life [5,6]. These observations have led to the proposal
that DIP is a major contributor to the high observed
prevalence of T2DM in indigenous populations and to
the increasing prevalence of obesity and diabetes among
their children [7]. Indigenous women in Australia,
Canada, New Zealand and the United States have
experienced rapid changes from a traditional diet and
lifestyle, to one rich in processed, carbohydrate-dense
foods and reduced energy expenditure, which are asso-
ciated with increased rates of obesity, GDM and T2DM
[8].
T2DM is a serious metabolic disorder, in which blood
sugar is no longer controlled, and can lead to heart dis-
ease, stroke, renal disease, kidney failure, amputations
and blindness [9]. The prevalence of T2DM is increasing
in line with increasing rates of obesity across the globe.
Indigenous populations generally have significantly
higher rates than non-indigenous people within the
same country, suggesting that indigenous populations
have progressed past the pre-diabetes stage in this meta-
bolic disorder [10].
The current recommendations for screening and diag-
nosis of GDM were written over 40 years ago by adapt-
ing methods for screening non-pregnant women in
order to identify those at high risk for T2DM after preg-
nancy [2]. Recently demonstrated clear associations
between any degree of hyperglycaemia and adverse preg-
nancy outcomes [11] has, however, led to a review of
these long-established criteria [12]. There is ongoing
controversy about use of universal or selective screening,
t h et i m i n ga n dt h et y p eo ft e s ts [13-15] and the choice
of interventions for prevention management and follow-
up, particularly for indigenous communities [16]. How-
ever, there appears to be consensus that women in
populations with a high prevalence of T2DM should be
offered screening for GDM early in pregnancy, before
an oral glucose tolerance test at 24-28 weeks gestation
(as is current practice), particularly if metabolic testing
in this age group is not commonly conducted [17,18].
The aim of population-based screening is to reduce
the burden of disease in the community by earlier detec-
tion of disease, thus providing an opportunity for inter-
vention and improvement of health-related outcomes
[19]. Early detection of GDM provides an opportunity
to offer support and treatment to reduce or manage
hyperglycaemia and the associated risks in both preg-
nancy and the long term. Pregnancy is an opportune
time to offer support to women, as they have frequent
scheduled contacts with health-care providers and are
often highly motivated to adapt their behaviour to
improve the health of their infant. In addition, any effec-
tive interventions could affect the health of the whole
family, including the unborn child [20,21].
A number of factors should be considered, however,
before introducing population-based interventions, includ-
ing; the prevalence and natural history of the condition,
current screening practice and rates, acceptability (prefer-
ences and values), efficacy and cost and the availability of
adequate treatment pathways and follow-up [22]. In addi-
tion to these routine criteria, there are specific considera-
tions related to screening in pregnancy and in indigenous
populations. Increased diagnosis in pregnancy of a medical
condition in a generally healthy population can be asso-
ciated with unnecessary stress [23], and ineffective therapy
might be given that initiates a “cascade of interventions”
[24] which interfere with the normal process of pregnancy
and birth. Indigenous communities in particular face a
range of exacerbated health challenges, with complex cul-
tural and social issues, which should be considered in any
medical intervention [25]. The current consensus makes it
likely that indigenous women will experience changes in
screening practice earlier than low-risk population groups.
However, the evidence that the criteria for population-
based screening are met for this population group has not
been reviewed, nor have the specific issues unique for this
population group.
T h ee v i d e n c ef o rt h e s ef a c t o r sw i l lb eg e n e r a t e db y
studies with a number of different designs, including
epidemiological studies, qualitative studies, measurement
studies, intervention studies and even opinion pieces.
Systematic review offers a rigorous process for apprais-
ing the quality of evidence; however, such reviews are
often restricted, as they include only a limited number
of study designs in order to focus on the internal valid-
ity of the design and not to consider the external valid-
ity or generalizability of the results for the intended
purpose [26]. Thus, researchers and journal editors face
challenges in making research relevant for decision-
making [26]. These challenges are familiar to clinicians
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number of tools have been developed to “GRADE” and
present evidence that may be useful for adaptation in
the public health setting [27].
Our aim in this paper is to describe a method for sys-
tematically reviewing all published studies relevant to
informing future discussions about screening for DIP
among indigenous women in Australia, Canada, New
Zealand and the United States.
Methods/Design
Inclusion criteria
The inclusion criterion will be broadly defined as “any
publication that includes analysis or discussion of dia-
betes in pregnancy among indigenous women in Austra-
lia, New Zealand, Canada or the United States”.
This broad definition was used so that all studies
would be included and information to address the rele-
vant screening criteria [22] could be extracted. This
includes information regarding perspectives and accept-
ability, which affect the overall sensitivity of screening
interventions when applied at a population level. The
body of literature therefore comprises all original inter-
vention, measurement and descriptive studies, as well as
reviews, program descriptions and opinion pieces. Indi-
genous women in Australia, Canada, New Zealand and
the United States were grouped, as they are considered
to have similar (but not identical) social and health
experiences of colonisation and rapid transition from a
traditional diet and lifestyle to one of relative poverty in
a high-income country [25,28,29]. In most published
studies, indigenous womenh a v eb e e nc o m p a r e dw i t h
non-indigenous women in the same countries, or evi-
dence for non-indigenous women was applied to indi-
genous women, with arguable external validity.
Search method
We will search the Cochrane Database of Systematic
Reviews (1995-July 2010), Medline (1950-July 2010),
Embase (1949-July 2010), CINAHL (1937-July 2010),
and PsychINFO (1905-July 2010). The following key
words in the titles and abstracts and subsequent MeSH
headings will be searched:
pregnan* or antenatal or prenatal, or neonatal or new-
born or infan* or fetal or fetus or foetal or foetus
AND diabet* or hyperglyc?mi* or glucose intoleran* or
obes* (or gestational diabet*)
AND aborigin* or indigen* or native* or first nation*
See table 1 for a full search tree in Medline. We will
not apply any language or other restrictions.
Data collection
Citations identified by the search of the five databases
will be downloaded into Endnote
© for removal of
duplications, and all abstracts will be reviewed by two
people to determine whether the publications potentially
meet the criterion for inclusion in this review.
The full text of all publications that potentially meet
the inclusion criterion will be reviewed by one assessor,
and 10% will be independently reviewed by a second
assessor for validation. When there is disagreement, a
third person will make the final decision. The propor-
tions of agreement between the first and second
reviewer and between the first and final reviewer will be
reported to provide an estimate of the degree of possible
variation in interpretation.
Kappa scores will not be calculated, as there is a high
rate of expected agreement that would require a larger
sample size of co-reviewed papers than is feasible within
the resource constraints of this review. All publications
that do not meet the inclusion criterion, with reasons
specified, will be available from the contact author on
request.
Data extraction
A spreadsheet will be prepared in Microsoft Excel
© to
extract standardised data items from the included publi-
cations. One person will extract data from all the
included publications, and 10% will be extracted inde-
pendently by a second reviewer and checked for agree-
ment. When there is disagreement, a third person will
make the final decision. The proportions of agreement
between the first and second reviewer and the first and
final reviewer will be reported in order to provide an
estimate of potential variation in interpretation. Again,
kappa scores will not be calculated because of the high
level of expected agreement.
Publications will be coded according to their focus on
indigenous people in the following countries:
Australia (Aboriginal and/or Torres Strait Islander);
Canada (Cree, Saskatchewan Indian, Saskatoon Indian,
Inuit, First Nation);
New Zealand (Maori);
United States (Navajo Indian, Papago, Athabaskan,
Chamorro, Chippewa, Pima Indian, Tohono Indian, Zuni
Indian, Hawaiin, Yup’ik Eskimo, Native Indian); and
“Other” (when more than one group or general refer-
ence is made).
Publications will be coded under one of the research
purposes [28-30] and study designs [31] outlined in
Table 2.
The following outcome data will be extracted: ratio-
nale, aims, number of people included, journal title, out-
comes reported, main findings and conclusions, funding
source, data source, GDM incidence, diagnostic criteria
used and years of measurement.
The publication topics will be grouped according to
the “key criteria“ of the population-based screening
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1. pregnan*.mp. [mp = title, original title, abstract, name of substance word, subject heading word, unique identifier]
2. exp Pregnancy/or exp Pregnancy Outcome/
3. antenatal.mp. [mp = title, original title, abstract, name of substance word, subject heading word, unique identifier]
4. exp Prenatal Care/or exp Prenatal Diagnosis/
5. prenatal.mp. [mp = title, original title, abstract, name of substance word, subject heading word, unique identifier]
6. exp Prenatal Nutritional Physiological Phenomena/or exp Prenatal Exposure Delayed Effects/
7. 1 or 2 or 3 or 4 or 5 or 6
8. neonatal.mp. [mp = title, original title, abstract, name of substance word, subject heading word, unique identifier]
9. newborn*.mp. [mp = title, original title, abstract, name of substance word, subject heading word, unique identifier]
10. exp Infant, Newborn/ab, an, cl, co, di, et, gd, me, mi, mo, pa, pd, ph [Abnormalities, Analysis, Classification, Complications, Diagnosis, Etiology,
Growth & Development, Metabolism, Microbiology, Mortality, Pathology, Pharmacology, Physiology]
11. infan*.mp. [mp = title, original title, abstract, name of substance word, subject heading word, unique identifier]
12. exp Infant/
13. fetus.mp. [mp = title, original title, abstract, name of substance word, subject heading word, unique identifier]
14. exp Fetus/
15. exp Fetal Development/
16. foetus.mp. [mp = title, original title, abstract, name of substance word, subject heading word, unique identifier]
17. exp Fetus/
18. foetal*.mp. [mp = title, original title, abstract, name of substance word, subject heading word, unique identifier]
19. 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18
20. 7 or 19
21. diabet*.mp. [mp = title, original title, abstract, name of substance word, subject heading word, unique identifier]
22. exp Diabetes Mellitus, Type 2/or exp Diabetes Complications/or exp Diabetes Mellitus/
23. 21 or 22
24. hyperglyc?mi*.mp. [mp = title, original title, abstract, name of substance word, subject heading word, unique identifier]
25. exp Hyperglycemia/
26. glucose intoleran*.mp. [mp = title, original title, abstract, name of substance word, subject heading word, unique identifier]
27. exp Glucose Intolerance/or exp Glucose Tolerance Test/
28. obes*.mp. [mp = title, original title, abstract, name of substance word, subject heading word, unique identifier]
29. exp Obesity/
30. 24 or 25 or 26 or 27 or 28 or 29
31. 23 or 30
32. gestational diabet*.mp. [mp = title, original title, abstract, name of substance word, subject heading word, unique identifier]
33. exp Diabetes, Gestational/
34. 32 or 33
35. aborigin*.mp. [mp = title, original title, abstract, name of substance word, subject heading word, unique identifier]
36. exp Indians, North American/or exp Oceanic Ancestry Group/
37. indigen*.mp. [mp = title, original title, abstract, name of substance word, subject heading word, unique identifier]
38. exp Health Services, Indigenous/
39. 35 or 36 or 37 or 38
40. 20 and 31
41. 34 or 40
42. 39 and 41
43. 31 and 39
44. 20 and 39
45. native*.mp. or exp American Native Continental Ancestry Group/
46. (45 and 41) not 39
Table 2 Coding of study designs for a review of diabetes in pregnancy among indigenous women
Research
purpose
Study design
Descriptive Descriptive (cross-sectional survey or qualitative study) or analytical (cohort study, case-control study or cross-sectional study with
control group)
Intervention Experimental (control group) or other
Measurement Screening test efficacy studies
Other Reviews, opinions, guidelines, etc.
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DIP, screening practice and rates, acceptability, efficacy
and cost (measurement), adequate treatment pathways,
systems for follow-up and “other” (including preventive
interventions).
Appraisal of external validity (generalisability)
The external validity will be appraised by coding the
studies according to:
whether the population is rural, urban, remote or
mixed; and
whether the data were collected from clinics, indivi-
dual communities or broader populations.
Appraisal of internal validity (risk for bias)
The risk for bias will be critically appraised with specific
tools for different study designs. Intervention and mea-
surement studies, reviews and qualitative descriptive stu-
dies will be appraised with the following tools:
Intervention studies will be appraised with the Centre
for Evidence-Based Medicine (CEBM) Critical Appraisal
Skills Programme (CASP) tool for intervention studies
[32].
Measurement studies will be appraised with the CEBM
CASP tool for studies of diagnostic accuracy [33].
Reviews will be appraised with the CEBM CASP tool
for systematic reviews [34].
Qualitative research will be appraised with tools
adapted from the Australian Department of General
Practice and other experts for qualitative studies [35,36].
As no tool exists for appraising descriptive studies, we
adapted an instrument from Strengthening the Report-
ing of Observational Studies in Epidemiology (STROBE)
[37], a recent systematic review of descriptive studies
[38] and a tool used by clinicians for rapid evidence
appraisal [39]. Our tool was developed specifically for
this review and pilot-tested with a sample of over 20
studies; it was subsequently modified, as some items
could not be appraised (e.g. reporting bias) (see Table
3).
Data analysis
Data will be analysed with Microsoft Excel
©.T h eo u t -
comes reported will include: the rates of publications
per country and over time, the type of research that has
been published, the internal validity and risks for bias
identified in the research, the published findings relevant
to population-based screening criteria and the generali-
sability of the findings.
A detailed “characteristics of included studies table”
will be available on request, in which the included stu-
dies will be summarised in alphabetical order with:
description of the population, study details, main find-
ings and a summary of the risks for bias.
The conclusions about the strength of the evidence
within each of the criteria will be clearly communicated
to the reader by presenting a summary table adapted
from the “GRADE” criteria, which is used to assess
guideline evidence [27,40] (see Table 4).
The summary of findings table will include columns
for each of the screening criteria, an evidence statement
for the main findings under each criterion (referenced),
a strength of evidence symbol and a comment about the
generalisability of each statement (i.e. remote, rural,
urban or mixed communities and country).
Discussion
This paper outlines a process for systematic review and
appraisal of both the internal and external validity of the
published literature and for presenting it in a framework
to inform decisions about population-based screening
for GDM among indigenous women in Australia,
Canada, New Zealand and the United States.
The heterogeneity of the study designs and the hetero-
geneity between studies of the same design (e.g. differ-
ent diagnostic criteria for GDM and different criteria for
identification of indigenous status both between coun-
tries and between studies in descriptive prevalence stu-
dies) will preclude a meta-analysis of the studies.
Nevertheless, the authors consider it valuable to present
a narrative synthesis of the relevant research that has
been published under each of the population-based
screening criteria.
Calculating kappa scores was not feasible, as the high
rate of expected agreement for some criteria would have
required co-review by a second person of approximately
half of the 123 included publications. Resources permit-
ting, it would be desirable to have all the data extracted
by two people.
The inclusion criterion for this review does not
include potentially relevant evidence on other popula-
tion groups or topics such as cancer screening. We do
not propose that the evidence from the published aca-
demic literature on a specific topic for population
groups with some similarities would, in itself, provide
sufficient information to enable informed decision-mak-
ing. However, this review should be a useful resource to
contribute to the evidence base for developing interven-
tions in this area.
The vast majority of the studies are observational,
descriptive and quantitative, for which there are no
commonly used or widely accepted critical appraisal
tools. The STROBE guidelines provide a useful reference
point; however, they are designed for reporting rather
than for the methods of research. The tool presented
here for appraising quantitative descriptive studies was
adapted for the studies in this review. Specific consid-
eration was paid to the potential for selection bias,
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Type of risk Low Moderate High
Selection (sampling of population) Consecutive unselected
population
Sample from general
population not a selected
group
Rationale for case and control
selection explained
Follow-up or assessment time
appropriate
Sample selected from large
population, but selection criteria
not defined
Sample selection ambiguous,
but may be representative
Eligibility criteria not described
Rationale for case and control
selection not described
Follow-up assessment not
appropriate
Analysis to adjust for sampling
strategy bias
Sample selection ambiguous,
and sample unlikely to be
representative
Highly selected population,
making it difficult to generalise
findings
Selection (sampling size) if non-significant
results; otherwise NA
Sample size calculation
conducted and adequate
Sample size calculation not
performed, but all eligible
persons studied
Sample size calculation
performed, and reasons for not
meeting sample size given
Sample size estimation unclear
or only subsample studied
Selection (participation rate) High participation rate (>
85%)
Moderate participation rate (70-
85%)
Low participation rate (> 70%)
Performance bias (outcome assessment) Diagnosis on basis of
consistent criteria and direct
examination
Assessment from hospital
record or by questioning
person
Assessment from administrative
database or register
Assessment from non-validated
data or generic estimate from
overall population
Performance bias (confounding factors) Control for common
confounders (e.g. risk factors)
Only certain confounders
adjusted (e.g. age)
Not controlled for any
confounders
Performance bias (blinding) when outcome
and exposure relations being assessed (e.g.
effect of GDM on offspring)
Outcome and exposure
assessment independently
blinded
Outcome and exposure
assessment independently
blinded
Performance bias (methods to control for
bias)
Analysis appropriate for type
of sample (e.g. subgroup
analysis/regression etc.)
Analysis did not account for
common adjustment
Data confusing
Attrition bias 0-10% attrition
All participants from initiation
to final outcome assessment
accounted for
Sensitivity analysis conducted
for missing data
11-20% attrition
No sensitivity analysis for
missing data
> 20% attrition and no
sensitivity analysis for missing
data
Other: for comparative studies Comparison groups similar at
baseline
Baseline characteristics of
comparison groups not
assessed
Baseline characteristics
dissimilar
Table 4 Classification of quality of evidence base for screening for gestational diabetes mellitus in indigenous women
GRADE
symbol
Level of
confidence in
quality of
evidence
Definition Criteria
⊕⊕⊕
⊕
High We are confident the true effect lies close to the estimate of
the effect.
One or more studies were appraised at low risk of
bias.
⊕⊕⊕ Moderate We are moderately confident in the effect estimate: the true
effect is likely to be close to the estimate of the effect, but
there is a possibility that it is substantially different.
No studies were appraised at low risk of bias,
although one or more studies were appraised at
moderate risk of bias.
⊕⊕ Low Our confidence in the effect estimate is limited: the true effect
may be substantially different from the estimate of the effect.
No studies were appraised as low or moderate risk
of bias. One or more studies were appraised at
high risk of bias.
⊕ Very low We have very little confidence in the effect estimate. The publications were not in a format that
allowed appraisal of the effect estimate (e.g.
opinion piece).
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criteria used for identifying indigenous status (e.g. blood
quantum specifications). As we were unable to develop
clear objective criteria for assessing analytical bias, we
adapted a tool that was already available [39]. As there
was insufficient information to assess reporting bias, this
aspect was removed after pilot-testing
One of the common criticisms of academic literature
is that the criteria for internal validity are too restrictive
and relevant evidence is not presented in a way that is
useful for policy-makers [26]. A strength of this review
is that a relevant framework is described, with criteria
[22] that define the range of study designs that should
be included. While consideration of a broad range of
study designs presents methodological challenges for
systematic reviews of the literature, the method
described here presents a means for rigorous appraisal
of the internal and external validity of the included
studies.
The method for our review was adapted to allow
inclusion of the perspectives and experiences of indi-
genous women and communities, which are clearly
relevant to policy-makers. At the time of writing, we
were unable to find any structured research about DIP
that was explicitly reported from an indigenous per-
spective, thus highlighting a critical gap, or “perspec-
tive bias”, in the research. This gap may be due to a
number of factors, such as an under-representation of
indigenous people in academic institutions, lack of
trust between indigenous communities and academic
institutions and the notion that “objectivity” is desir-
able in public health research, thus negating the valid-
ity of perspectives.
Indigenous women in Australia, Canada, New Zeal-
and and the United States have one of the highest pre-
valence rates of T2DM in the world; therefore, there is
consensus that they should be offered changes to cur-
rent screening practice in the near future. However,
there are unique social and health considerations for
this vulnerable population group which requires active
collaboration and careful reflection on the existing evi-
dence base. Policy-makers need information presented
i naf o r m a tt h a ti su s e a b l ea n dt h a ti n c l u d e sall the
relevant data for which both the internal and external
validity have been rigorously appraised and the evi-
dence gaps clearly identified, to ensure that decisions
made on the basis of limited evidence are carefully
evaluated.
This paper has described a process of adapting rigor-
ous systematic review methods to include different
study designs, in order to produce relevant evidence for
a contemporary discussion about screening policies for
DIP among pregnant indigenous women.
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